GLP-1 / glucagon dual agonist
Survodutide
Also known as BI 456906.
Stage Phase 3
Indications Obesity, MASH
Last updated:Jul 15, 2026Source:ClinicalTrials.gov + sponsor pipeline pagesVerified:Manually reviewedData provider:PeptidePlanet Research
Mechanism
Dual agonist under evaluation for obesity and MASH.
Educational summary. Not medical advice. See sponsor materials and peer-reviewed literature for full pharmacology.
Companies developing it
1Related trials
1Current research
Data unavailableCurated peer-reviewed research links launch once our editorial pipeline is verified.
Safety summary
Data unavailableSafety summaries require a verified regulatory data source and clinical review. Consult the FDA label and sponsor prescribing information for approved products.